Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck KGaA | 3,916 |
| 2 | BASF SE | 2,754 |
| 3 | Takeda Pharmaceutical Co Ltd | 2,038 |
| 4 | Bristol Myers Squibb Co | 1,992 |
| 5 | Merck and Co Inc | 1,967 |
| 6 | Bayer AG | 1,765 |
| 7 | Fujifilm Holdings Corp | 1,144 |
| 8 | Sanofi SA | 913 |
| 9 | Incyte Corp | 900 |
| 10 | Astellas Pharma Inc | 748 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C07D | Heterocyclic compounds | 34,980 |
| 2 | A61P | Therapeutic activity (drug indications) | 27,635 |
| 3 | A61K | Medicinal preparations | 18,152 |
| 4 | C07C | Acyclic and carbocyclic compounds | 6,374 |
| 5 | A01N | Preservation of bodies; biocides; pest repellents | 5,723 |
| 6 | C09K | Materials for misc. applications | 5,568 |
| 7 | H10K | Organic semiconductors / OLEDs | 4,827 |
| 8 | C07F | Organometallic compounds | 4,711 |
| 9 | Y02E | Climate change mitigation: energy | 4,185 |
| 10 | Y02P | Climate change mitigation: production | 1,800 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Polymer of 1,2,4-thiadiazole and lubricants containing it as an additive | 1978 | Arkema SA | 69 |
| Novel disulfides derived from 1,2,4-thiadiazole | 1975 | Berkshire Hathaway Inc | 54 |
| 1,2,4-THIADIAZOLE DERIVATIVES ANTIFUNGAL COMPOUNDS, COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | 2007 | 44 | |
| 3,5-Di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxiphenyl- 1,2,4-thiadiazoles, -oxadiazoles as antiinflammatory agents | 1990 | Pfizer Inc | 33 |
| 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents | 1992 | Pfizer Inc | 31 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Hamish Ross | Johnson & Johnson (United States) | 2 |
| 2 | Williams Porcal | Instituto de Química Médica | 2 |
| 3 | William V. Murray | Johnson & Johnson (United States) | 2 |
| 4 | Ellen Sieber-McMaster | Johnson & Johnson (United States) | 2 |
| 5 | Lubing Zhou | Johnson & Johnson (United States) | 2 |
| 6 | Jolanta Wodzinska | Apotex (Canada) | 2 |
| 7 | Arantxa Encinas | Instituto de Química Médica | 2 |
| 8 | Ronald K. Russell | Johnson & Johnson (United States) | 2 |
| 9 | Patricia D. Pelton | Johnson & Johnson (United States) | 2 |
| 10 | Lan Shen | Johnson & Johnson (United States) | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles | 2005 | 156 | Synthesis and biological activity |
| Cu(II)- and Hg(II)-Induced Modulation of the Fluorescence Behavior of a Redox-Active Sensor Molecule | 2001 | 124 | Electrochemical sensors and biosensors |
| 1,2,4-Thiadiazole: A novel Cathepsin B inhibitor | 2003 | 82 | Protease and Inhibitor Mechanisms |
| Synthesis and evaluation of novel dipeptide-bound 1,2,4-Thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase | 2001 | 57 | Blood properties and coagulation |
| A Rational Chemical Intervention Strategy To Circumvent Bioactivation Liabilities Associated with a Nonpeptidyl Thrombopoietin Receptor Agonist Containing a 2-Amino-4-arylthiazole Motif | 2007 | 54 | Platelet Disorders and Treatments |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of 1,2,4-thiadiazole?
Which companies hold the most patents involving 1,2,4-thiadiazole?
How many patents involving 1,2,4-thiadiazole have been filed in the last three years?
What are the primary patent classification areas for 1,2,4-thiadiazole compounds?
What therapeutic applications of 1,2,4-thiadiazole have been documented in published research?